Selected article for: "acute respiratory syndrome and lopinavir ritonavir rct"
Author: Gul, Muhammad Hamdan; Htun, Zin Mar; Shaukat, Nauman; Imran, Muhammad; Khan, Ahmad
Title: Potential specific therapies in COVID-19
  • Cord-id: wjudxhdy
  • Document date: 2020_5_21
    • ID: wjudxhdy
    Snippet: COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potentia
    Document: COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mechanism and acute respiratory distress treatment: 1
    • action mechanism and adenosine analog: 1, 2
    • action mechanism and liver enzyme: 1
    • action mechanism and liver function: 1
    • action mechanism and long safety track record: 1
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active metabolite and acute lung injury: 1, 2
    • active metabolite and acute respiratory distress: 1, 2, 3
    • active metabolite and adenosine analog: 1
    • active metabolite and liver function: 1, 2, 3
    • active metabolite and lopinavir ritonavir: 1
    • active research and acute lung injury: 1, 2
    • active research and acute respiratory distress: 1, 2, 3, 4
    • active research and lopinavir ritonavir: 1
    • active research area and acute respiratory distress: 1
    • acute lung injury and lopinavir ritonavir: 1, 2, 3, 4, 5
    • acute respiratory distress and liver function test: 1, 2
    • acute respiratory distress and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25